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To estimate failure rates after treatment with benzathine 
penicillin and to identify determinants of failure that affected 
outcomes for yaws, we conducted a cohort study of 138 
patients; treatment failed in 24 (17.4%). Having low initial 
titers on Venereal Disease Research Laboratory test and 
living in a village where yaws baseline incidence was high 
were associated with increased likelihood of treatment 
failure.  
Y
aws is a tropical infection of the skin and bones 
caused by Treponema pallidum subsp. pertenue and 
is transmitted by direct, nonsexual contact with infectious 
lesions (1,2). Although a multinational mass eradication 
campaign in the 1950s greatly reduced the incidence of this 
disease (3–5), a resurgence of yaws has occurred in west 
and central Africa, Southeast Asia, and the Paciﬁ  c Islands 
(6–9). The currently recommended drug therapy for yaws 
is penicillin G benzathine, administered intramuscularly as 
a single dose of 1.2 million units (3,5). T. pallidum is a 
primary human pathogen that has eluded in vitro cultivation 
(10). Hence, although penicillin treatment failure has been 
reported for yaws (11), to date penicillin resistance has 
not been proven. Most serologically deﬁ  ned  treatment 
failures are thought to be caused by either reinfection 
after treatment or patient-to-patient variation in the rate 
of decline in nontreponemal test titers after treatment (i.e., 
>4-fold decrease), rather than by relapse (10). The aim of 
this study was to estimate failure rates after treatment with 
benzathine penicillin and to identify determinants of failure 
that affected the outcome.
The Study
We conducted a retrospective cohort study involving 
patients diagnosed with yaws at Lihir Medical Centre from 
January through September 2009. Ethics approval was 
obtained from the Papua New Guinea Ministry of Health 
Medical Research Advisory Committee. Diagnosis of yaws 
was based on correlation of the clinical ﬁ  ndings, positive 
serologic results, and epidemiologic history. Patients <15 
years of age whose mothers had negative treponemal test 
results at antenatal screening, with clinical evidence of early 
yaws (primary or secondary stage), and whose Venereal 
Disease Research Laboratory (VDRL) and T. pallidum 
hemagglutination test results were positive, were eligible 
to participate in the study. We included only case-patients 
with clear documentation of the village of residence, contact 
history, yaws clinical stage, clinical outcome, pretreatment 
titer, and at least 1 follow-up titer 12–15 months after 
treatment. We also estimated the minimum incidence rate 
for each of the 27 villages served by our hospital; a high 
incidence rate was deﬁ  ned as >1.5%. This percentage was 
calculated by dividing the number of new cases diagnosed 
at Lihir Medical Centre within the study period by the 
estimated population from each village, according to the 
local annual census. Treatment outcome was measured at 
a follow-up visit 12–15 months after treatment. Treatment 
failure was deﬁ  ned as the lack of a 4-fold decrease in 
VDRL titers at least 365 days after treatment. 
A total of 138 patients were identiﬁ  ed  during 
enrollment. Table 1 summarizes patient demographic 
characteristics, clinical signs and symptoms, laboratory 
results, and outcomes. Eighty-one (58.7%) persons 
displayed active primary cutaneous yaws lesions (Figure 
1), and 63 (45.7%) exhibited signs of secondary stage 
yaws (hyperkeratotic skin papules or bone involvement). 
All patients were administered 3 doses of intramuscular 
benzathine penicillin 1×/wk, and only 6 (4.4%) children 
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Table 1. Demographic data, clinical signs/symptoms, laboratory 
results, and outcome after treatment of yaws in 138 case-
patients, Papua New Guinea, January–September, 2009* 
Characteristic
Total no. (%) 
patients, N = 138 
Mean age, y (SD)  9.6 (4.4) 
Male sex  81 (58.7) 
VDRL titer 
 16  54  (39.1) 
 32  33  (23.9) 
 64  42  (30.4) 
 128  9  (6.5) 
Primary skin lesion  81 (58.7) 
Secondary stage  63 (45.7)† 
Family history  36 (26.1) 
Treatment with IM penicillin G benzathine  138 (100.0) 
Clinical healing  132 (95.7) 
Concurrent disease  7 (5.1)‡ 
Seroconversion 63 (45.7) 
Serologically defined treatment failure  24 (17.4) 
*VDRL, Venereal Disease Research Laboratory; IM, intramuscular. 
†Includes 7 cases of early yaws osteoperiostitis, among  whom were 3 
patients with dactylilitis. 
‡Includes 3 cases of Plasmodium falciparum malaria, 1 case of P. vivax
malaria, 1 case of acute diarrhea diagnosed at the 12-month follow-up 
visit, and 2 case-patients with a chronic underlying disease (1 case of 
congenital heart disease and 1 case of chronic asthma). required 1 or 2 additional doses before initial symptoms 
disappeared. According to the estimated minimum 
incidence, in 9 villages the disease was classiﬁ  ed as highly 
endemic, and in 15 villages, the disease was considered 
of low endemicity (Figure 2). Of the 138 analyzed case-
patients, 90 (65.2%) persons came from a high minimum 
incidence village (HMIV) and 48 (34.8%) came from a 
low minimum incidence village (LMIV). Secondary stage 
lesions were found in 47 (52.2%) of 90 case-patients 
among the HMIV group and only in 16 (33.3%) of 40 case-
patients in the LMIV group (p = 0.035). VDRL titers were 
signiﬁ  cantly lower in case-patients in the HMIV group than 
in those in the LMIV group; 70% of case-patients in the 
HMIV group had a titer <32 (p = 0.026), as did 50% of 
those in the LMIV group. A positive association between 
a low initial VDRL titer and secondary stage disease was 
also found (79% of case-patients with secondary yaws had a 
low initial titer, compared with 51% who had primary yaws 
[p<0.01]). Overall, 24 (17.4%) case-patients experienced 
serologically deﬁ  ned treatment failure during follow-up, 
including 21 (23.3%) and 3 (6.3%) from the HMIV and 
LMIV groups, respectively. Multivariate analysis (Table 
2) showed that only residence in a high incidence village 
(odds ratio 3.75, 95% conﬁ  dence interval 1.02–13.76) and 
an initial VDRL titer <32 (odds ratio 4.05, 95% conﬁ  dence 
interval 1.06–15.38) proved to be independent predictors 
for treatment failure.
Conclusions
Serologically deﬁ   ned treatment failures occurred in 
≈17% of case-patients in our series. Treatment failure could 
have been inﬂ  uenced by the capacity of the infecting agent 
to develop resistance to the antimicrobial drug used, or 
the failure could have been caused by other factors related 
to the human host. Our ﬁ  ndings show that in Lihir, the 
factors predicting treatment failure after 12 months of drug 
therapy were the following: residence in a village where 
incidence of infection was high and initial VDRL titer was 
low. False-positive VDRL reactions, classically associated 
with viral and autoimmune diseases (12), are unlikely to 
be the cause of failure in our series, because no chronic 
underlying disease or concurrent febrile illnesses were 
registered in 23 (96%) of the case-patients who did not 
achieve a cure. Moreover, the strict epidemiologic criteria 
required (obtained through patient history) for inclusion in 
the study aimed to reduce the likelihood of false-positive 
results for syphilis. A VDRL titer of <32 dilutions proved 
to be a robust predictor of failure. 
In our experience, this low titer is also associated with 
longer lasting infections and is more commonly found in 
high incidence villages (as are longer lasting infections). 
Even after multivariate analysis, clarifying the role of 
these confounding factors is difﬁ  cult. We suspect that the 
true factor at work here rests upon the assumption that a 
chronic infection is more difﬁ  cult to resolve. The tissue-
to-plasma ratios for bone penetration are usually between 
0.1 and 0.3 for penicillins and are even lower for cortical 
bone than for cancellous bone (13). On the basis of these 
ratios, treponemes that invade the bone would encounter 
subtherapeutic levels of penicillin, which could simply lead 
to persistent infection or even provide selective pressure 
for mutations for penicillin resistance. On the other hand, 
the risk for reinfection caused by repeated contact with 
infected children seems to be a pivotal factor in predicting 
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Figure 1. Painless ulcer with raised edges corresponding to a 
primary yaws skin lesion on an infant case-patient’s leg, Papua 
New Guinea, 2009. Source of photograph: Lihir Medical Centre, 
Dr Oriol Mitjá.
Figure 2. Map of Lihir Island, Papua New Guinea, showing 
incidence of infection in the 24 villages where cases of yaws were 
diagnosed, 2009. Lihir Medical Center is located in Londolovit 
village. Incidence proportions are shown within parentheses.Outcome Predictors, Yaws
treatment failure. The high number of asymptomatic 
persons or persons with few symptoms in high prevalence 
areas is the main reservoir of the infection and a known 
obstacle to achieving the eradication of yaws. A limitation 
of our study is the use of incidence rates derived from 
hospital-based detected cases, which likely underestimated 
the real incidence of infection. Also, the calculation of this 
proportion might be less precise because we did not take 
into account factors such as the distance of the village from 
the health center or the proportion of children to adults in a 
particular village.
On the basis of our ﬁ   ndings, we anticipate that a 
community-based strategy will be required to effectively 
control yaws on Lihir Island. The current strategy 
for eradication of yaws in areas where the disease is 
moderately endemic (prevalence <5%) is to treat patients 
with active cases and their contacts. In our experience, 
most children did not have a family history of yaws. 
Thus, the disease likely is not clustered in households 
but, rather, transmission is more likely to occur among 
children in the community, in schools, and in other public 
places. Future eradication programs will need to take into 
account all epidemiologic, biological, and pharmacologic 
factors, along with the practical considerations of a mass 
campain to deliver and administer drugs in isolated and 
underresourced communities. In this context, the potential 
treating yaws with oral, single-dose therapy, for example, 
with azithromycin, should be explored.  
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Table 2. Association between characteristics of case-patients and Treponema pertenue infection treatment failure, Papua New 
Guinea, January–September 2009* 
Characteristic
No. (%) patients treated  Univariate analysis  Multivariate analysis 
Success, n = 114  Failure, n = 24  OR (95% CI)  p value OR (95% CI)  p value 
Mean age, y (SD)  9.54 (4.69)  10.13 (2.96)  0.58 (1.39 to 2.56) 0.56 NA NA
Male sex  69 (60.5)  12 (50.0)  0.65 (0.27–1.58)  0.34 NA NA
Lived in a high-incidence 
village 
69 (60.5)  21 (87.5)  4.57 (1.29–16.20)  0.02 3.75 (1.02–13.76)  0.04
Secondary yaws  49 (43.0)  14 (58.3)  1.86 (0.76–4.53)  0.17 1.01 (0.37–2.75)  0.99
Clinical healing 108 (94.7)  24 (100.0)  NA 0.59 NA NA
Positive family history  27 (23.7)  9 (37.5)  1.93 (0.76–4.91)  0.17 1.91 (0.70–5.28)  0.20
VDRL titer <32  67 (58.8)  21 (87.5)  4.91 (1.39–17.41)  0.01 4.05 (1.06–15.38)  0.04
*p<0.05 was considered significant. OR, odds ratio; CI, confidence interval; NA, not applicable; VDRL, Venereal Disease Research Laboratory test.   
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